IMPACT BIOMEDICAL INC. (IBO) — Institutional Holders, Q2 2026
23 institutional investment managers reported a IBO position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $1.8M. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
IBO in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
New positions
3
Added to
4
Trimmed
5
Sold out
0
Biggest buyers
- VANGUARD CAPITAL MANAGEMENTAdded · +100,521 sh+$46.2K
- CITADEL ADVISORSNew · +49,567 sh+$22.8K
- JANE STREET GROUPNew · +24,528 sh+$11.3K
- VANGUARD FIDUCIARYAdded · +4,230 sh+$1.9K
- MORGAN STANLEYAdded · +11 sh+$5.00
Biggest sellers
- UBS Group AGTrimmed · -30,017 sh-$13.8K
- TWO SIGMA INVESTMENTSTrimmed · -20,236 sh-$9.3K
- NORTHERNTrimmed · -8,468 sh-$3.9K
- GEODE CAPITAL MANAGEMENTTrimmed · -7,762 sh-$3.6K
IBO 13F holders ranked 1–23 of 23
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT#1 · 1,185,163 sh | 1,185,163 | $545.6K | 0.00% | -0.7% |
| 2 | VANGUARD CAPITAL MANAGEMENT#2 · 808,689 sh | 808,689 | $372.0K | 0.00% | +14.2% |
| 3 | STATE STREET#3 · 607,897 sh | 607,897 | $279.6K | 0.00% | 0.0% |
| 4 | VANGUARD FIDUCIARY#4 · 589,428 sh | 589,428 | $271.1K | <0.01% | +0.7% |
| 5 | BlackRock#5 · 259,946 sh | 259,946 | $119.6K | 0.00% | 0.0% |
| 6 | NORTHERN#6 · 235,475 sh | 235,475 | $108.3K | 0.00% | -3.5% |
| 7 | CITADEL ADVISORS#7 · 49,567 sh | 49,567 | $22.8K | 0.00% | New |
| 8 | Vanguard Global Advisers#8 · 32,201 sh | 32,201 | $14.8K | 0.00% | 0.0% |
| 9 | JANE STREET GROUP#9 · 24,528 sh | 24,528 | $11.3K | 0.00% | New |
| 10 | TWO SIGMA INVESTMENTS#10 · 17,191 sh | 17,191 | $7.9K | 0.00% | -54.1% |
| 11 | Mason & Associates#11 · 10,000 sh | 10,000 | $4.6K | <0.01% | 0.0% |
| 12 | MORGAN STANLEY#12 · 9,285 sh | 9,285 | $4.3K | 0.00% | +0.1% |
| 13 | UBS Group AG#13 · 2,400 sh | 2,400 | $1.1K | 0.00% | -92.6% |
| 14 | Global Asset Management#14 · 1,818 sh | 1,818 | $836.00 | — | 0.0% |
| 15 | FMR#15 · 292 sh | 292 | $134.00 | 0.00% | +0.7% |
| 16 | WELLS FARGO & COMPANY#16 · 224 sh | 224 | $103.00 | 0.00% | 0.0% |
| 17 | Newbridge Financial Services Group#17 · 86 sh | 86 | $40.00 | — | 0.0% |
| 18 | Burk#18 · 27 sh | 27 | $12.00 | 0.00% | 0.0% |
| 19 | Center for Financial Planning#19 · 0 sh | 0 | $1.00 | — | New |
| 20 | DANSKE BANK A/S#20 · 3 sh | 3 | $1.00 | 0.00% | 0.0% |
| 21 | ROYAL BANK OF CANADA#21 · 32 sh | 32 | $0.00 | 0.00% | 0.0% |
| 22 | Ronald Blue#22 · 1 sh | 1 | $0.00 | — | New |
| 23 | CITIGROUP#23 · 1 sh | 1 | $0.00 | 0.00% | -99.7% |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.